Esphera SynBio specializes in synthetic biology, focusing on the modification of cells to produce engineered exosomes for therapeutic applications. Their technology involves designing transgenes that encode multimeric proteins, which are incorporated into exosomes. These engineered exosomes can be tailored with specific targeting moieties on their surface and can carry various protein or RNA payloads, such as siRNA, mRNA, or therapeutic enzymes. This innovative approach allows for the production of therapeutic exosomes either in vitro, using bioreactors, or in vivo, following the delivery of transgenes via different vectors.

A key application of Esphera's technology is the modification of tumor cells to convert typically immunosuppressive tumor-derived exosomes into immunostimulatory agents. This transformation aims to enhance the immune response against tumors, effectively creating personalized cancer vaccines that target the tumor microenvironment (TME). By leveraging their expertise in synthetic biology, Esphera SynBio is positioned to advance the treatment and prevention of diseases, particularly in the realm of cancer immunotherapy.

Canada

Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications.

Esphera SynBio

Company Details